{
    "clinical_study": {
        "@rank": "131145", 
        "acronym": "EFFORT", 
        "arm_group": [
            {
                "arm_group_label": "Intensive Exercise Group", 
                "arm_group_type": "Experimental", 
                "description": "Behavioral"
            }, 
            {
                "arm_group_label": "Current Recommendations Exercise Group", 
                "arm_group_type": "Experimental", 
                "description": "Behavioral"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of exercise on Insulin Resistance (IR)\n      in subjects who do not routinely exercise and who are at risk of developing diabetes\n      (prediabetes).\n\n      It is estimated that approximately 30-90 people will participate in this study at three\n      study sites in the United States and United Kingdom."
        }, 
        "brief_title": "Effect of Exercise on Insulin Resistance", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prediabetic State", 
        "condition_browse": {
            "mesh_term": [
                "Insulin Resistance", 
                "Prediabetic State"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Aged 18 to 75 years.\n\n          2. Meets one of the three diagnostic criteria listed below (based on screening results\n             or recorded result within one week of enrollment);\n\n               1. Fasting plasma or whole blood glucose (fasting defined as no caloric intake for\n                  at least 8 hours): 100 \u2264 125 mg/dL (6.0-6.9 mmol/L)\n\n               2. HbA1c of 5.7% - 6.4% (39 - 46 mmol/mol)\n\n               3. 2-hour plasma glucose of 140-199 mg/dL (7.8-11.0 mmol/L) during an OGTT (as\n                  described by the WHO using a glucose load of 75 g anhydrous glucose dissolved in\n                  water)\n\n          3. No clinically significant adverse exercise response during the maximal graded\n             exercise test\n\n        Exclusion Criteria\n\n          1. Weight loss diet program or weight change (>10%) within the past 6 months\n\n          2. Daily physical activity of >10,000 steps per day (as measured during the interval\n             between visits 1 and 2)\n\n          3. Participates in deliberate structured exercise\n\n          4. Pregnant or intending to become pregnant\n\n          5. Cognitive or intellectual disability that prevents subject from providing informed\n             consent or following protocol instructions.\n\n          6. Unwillingness to participate in all study procedures\n\n          7. Inability to give blood through multiple venous phlebotomies or to have an\n             intravenous catheter\n\n          8. BMI greater than 40 kg/m2\n\n          9. Concurrent participation in another lifestyle modification trial\n\n         10. Diagnosis of diabetes based on any one of the following criteria:\n\n               1. Fasting plasma or whole blood glucose \u2265 126 mg/dL (7 mmol/L)\n\n               2. HbA1c of >6.5% (>47 mmol/mol)\n\n               3. 2-hour plasma glucose \u2265 200 mg/dL (11.1 mmol/L) during an OGTT\n\n         11. Any pre-existing or newly discovered medical condition that is deemed likely to put\n             the subject at risk of injury during this trial.  This may include but is not limited\n             to:\n\n               1. Clinically relevant vascular or cerebrovascular event (e.g. stroke, recurrent\n                  transient ischemic attack  (TIA), deep venous thrombosis or intracardiac\n                  thrombi, clinically significant edema within the previous 6 months\n\n               2. Current use of anti-psychotic, anti-convulsant, anti-coagulant, sedative\n                  medication, or cognition-enhancing medications\n\n               3. Current use of beta blockers (beta-adrenergic blocking agents)\n\n               4. Current or previous use (within the past year) of the following medications:\n                  diabetes related medications or insulin; metformin; growth hormone; glucagon;\n                  dipeptidyl peptidase-4(DPP-4) inhibitors (saxagliptin, stigagliptin);\n                  glucagon-Like Peptide-1(GLP-1) mimetics (exenatide, liraglutide); sulfonylurea\n                  medication or other potential confounding medications\n\n               5. Medical conditon which predetermines insulin resistance (e.g. Marfan syndrome /\n                  severe Polycystic ovary syndrome (PCOS) / Cushing syndrome etc.).\n\n               6. Fasting triglycerides > 1000 mg/dL."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941277", 
            "org_study_id": "BSTE-0902"
        }, 
        "intervention": [
            {
                "arm_group_label": "Current Recommendations Exercise Group", 
                "intervention_name": "Current Recommendations Exercise Group", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Intensive Exercise Group", 
                "intervention_name": "Intensive Exercise Group", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 10, 2013", 
        "location": [
            {
                "contact": {
                    "email": "rlbrazg@rainier-research.com", 
                    "last_name": "Ronald Brazg, M.D", 
                    "phone": "425-251-1720"
                }, 
                "facility": {
                    "address": {
                        "city": "Renton", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98057"
                    }, 
                    "name": "Rainier Clinical Research Center"
                }, 
                "investigator": {
                    "last_name": "Ronald Brazg, M.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M23 9QZ"
                    }, 
                    "name": "Manchester University"
                }, 
                "investigator": {
                    "last_name": "Martin Gibson, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Trenell, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Newcastle upon Tyne", 
                        "country": "United Kingdom", 
                        "zip": "NE1 7RU"
                    }, 
                    "name": "Move Lab"
                }, 
                "investigator": {
                    "last_name": "Michael Trenell, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Exercise on Insulin Resistance", 
        "overall_contact": {
            "email": "devon.payne@alere.com", 
            "last_name": "Devon S Payne, BA", 
            "phone": "5037478132"
        }, 
        "overall_contact_backup": {
            "email": "jane.edwards@alere.com", 
            "last_name": "Jane Edwards", 
            "phone": "8588052715"
        }, 
        "overall_official": [
            {
                "affiliation": "Alere San Diego", 
                "last_name": "Rick San George, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Rainier Clinical Research Center", 
                "last_name": "Ronald L Brazg, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Newcastle University", 
                "last_name": "Michael Trenell, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "A decrease in Insulin Resistance (IR) as measured by a change in IR.", 
            "safety_issue": "No", 
            "time_frame": "change between baseline and 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941277"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alere San Diego", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alere San Diego", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}